When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
H. Lundbeck A/S (OTC:HLUKF) has agreed to acquire Alder BioPharmaceuticals (NASDAQ:ALDR) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total value of the transaction is up to $1.95B.
More news on: H. Lundbeck A/S, Alder BioPharmaceuticals, Inc., H. Lundbeck A/S, Healthcare stocks news, Merger & acquisition news, Stocks on the move,